JPMorgan Chase & Co. Reaffirms Buy Rating for MorphoSys (MOR)
A number of other research firms also recently weighed in on MOR. Berenberg Bank set a €85.00 ($101.19) price target on shares of MorphoSys and gave the stock a buy rating in a research note on Thursday, December 7th. Commerzbank set a €76.00 ($90.48) price target on shares of MorphoSys and gave the stock a buy rating in a research note on Tuesday, November 7th. Goldman Sachs Group set a €55.00 ($65.48) price target on shares of MorphoSys and gave the stock a neutral rating in a research note on Tuesday, September 19th. Deutsche Bank set a €90.00 ($107.14) price target on shares of MorphoSys and gave the stock a buy rating in a research note on Monday, October 30th. Finally, Oddo Bhf set a €81.00 ($96.43) price target on shares of MorphoSys and gave the stock a buy rating in a research note on Monday, September 25th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. MorphoSys currently has an average rating of Buy and an average target price of €83.75 ($99.70).
MorphoSys (ETR MOR) traded up €0.50 ($0.60) on Monday, reaching €85.80 ($102.14). 114,486 shares of the company’s stock were exchanged, compared to its average volume of 125,412. MorphoSys has a 1 year low of €47.10 ($56.07) and a 1 year high of €86.75 ($103.27). The firm has a market capitalization of $2,540.00 and a P/E ratio of -29.08.
TRADEMARK VIOLATION NOTICE: This story was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://theolympiareport.com/2018/01/16/jpmorgan-chase-co-reaffirms-buy-rating-for-morphosys-mor.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.